Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATH3G10 in STEMI patients undergoing PCI
NL-OMON48214Phase 2Active, not recruiting
- Sponsor
- Athera Biotechnologies AB
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing ATH3G10 with Placebo (2 arms). Primary endpoints: Change in left ventricular end-diastolic volume index and Safety and tolerability. Started Oct 2019; status: active, not recruiting.
02
Drugs
ABR-001
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON48214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48214.